Background/Aims: Thyroid cancer is one of the most prevalent endocrine tumors. The present study examined the effects of lncRNA HOXA cluster antisense RNA2 (HOXA-AS2) on the progression of papillary thyroid cancer (PTC), and explored the underlying molecular mechanisms. Methods: Quantitative real-time PCR was used to detect HOXA-AS2, miR-520c-3p and S100 calcium-binding protein A4 (S100A4) expression. Furthermore, the effects of HOXA-AS2 silencing and overexpression on cell proliferation, migration, and invasion were assessed in PTC in vitro by CCK8 and transwell assay. Furthermore, bioinformatics online programs predicted and luciferase reporter assay were used to validate the association of HOXA-AS2 and miR-520c-3p in PTC. Results: We observed that HOXA-AS2 was up-regulated in PTC tissues. In vitro experiments revealed that HOXA-AS2 knockdown significantly inhibited cell growth in PTC in vitro and in vivo. Further functional assays indicated that HOXA-AS2 significantly promoted PTC cell migration and invasion by promoting EMT. Bioinformatics online programs predicted that HOXA-AS2 sponge miR-520c-3p at 3'-UTR with complementary binding sites, which was validated using luciferase reporter assay. HOXA-AS2 could negatively regulate the expression of miR-520c-3p in PTC cells. MiR-520c-3p was down-regulated in PTC tissues, and S100A4 was predicted as a downstream target of miR-520c-3p, which was confirmed by luciferase reporter assay. Conclusion: In summary, our results suggested that the HOXA-AS2/miR-520c-3p/S100A4 axis may play an important role in the regulation of PTC progression, which provides us with new insights into understanding the PTC.
Introduction
Thyroid cancers of follicular cell origin are the most common endocrine malignancies. The dominant histological type of thyroid carcinoma is papillary thyroid carcinoma (PTC) that accounts for 80-85% of all cases [1, 2] . Although the overall 5-year survival rate of PTC exceeds the rate for most other cancers, the development of metastasis continues to be the most significant cause in thyroid cancer mortality [3] . The tumour invasion and metastases of PTC is a complex process involving the proliferation and detachment of tumour cells, breaking of the extracellular matrix, angiogenesis, hematogenous and lymphatic dissemination, invasion of the surrounding extracellular matrix, angiogenesis, vascular or lymphatic dissemination, and eventually, homing in distant tissues, and proliferation at novel sites that eventually results in metastatic tumors [4] . The molecular mechanism underlying PTC metastasis still remains elusive. Thus, it is important to identify genes involved in this process and develop new strategies to PTC treatment.
Long noncoding RNA (lncRNA) is a type of noncoding RNA greater than 200 nucleotides in length [5, 6] . LncRNA could regulate the gene expression at the transcriptional or posttranscriptional level by acting as microRNA (miRNA) sponges [7] . Abnormal lncRNA expressions have been reported to be upregulated in various cancers, including PTC [8] [9] [10] .
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Cellular Physiology and Biochemistry Cell culture and reagents Four PTC cell lines (BHP5-16, TPC, K1 and BHP2-7) and a normal human thyroid epithelium cell line (Nthy-ori 3-1) were from the tumor cell bank of Chinese Academy of Sciences. Cells were cultured in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (Gibco) 100 U/ml penicillin, and 100 mg/ ml streptomycin (Invitrogen) in humidified air at 37°C with 5% CO2. Hsa-miR-520c-3p mimics, hsa-miR520c-3p inhibitor, pcDNA3.1/HOXA-AS2 plasmid and negative control miRNA (miR-nc) were chemically synthesized by Shanghai Integrated Biotech Solutions Co., Ltd. (Shanghai, China).
RNA extraction and qRT-PCR assays
Total RNA was extracted from tissues or cultured cells using TRIZOL reagent (Invitrogen). For qRT-PCR, RNA was reverse transcribed to cDNA by using a Reverse Transcription Kit (Takara, Dalian, China). Real-time PCR analyses were performed with SYBR Premix Ex Taq (Takara, Dalian China). Results were normalized to the expression of GAPDH. The sequence of the primers were as following: HOXA-AS2 (Forward: 5'-CCCGTAGGAAGAACCGATGA-3', Reverse: 5'-TTTAGGCCTTCGCAGACAGC-3') and GAPDH (Forward: 5'-GGGAGCCAAAAGGGTCAT-3', Reverse: 5'-GAGTCCTTCCACGATACCAA-3'). The qRT-PCR assays were conducted on an ABI 7500 (Life Technologies, Carlsbad, CA, USA), and data collected with this instrument. Our qRT-PCR results were analyzed and expressed relative to threshold cycle (CT) values, and then converted to fold changes.
Transfection
Cells were seeded in 6-well dishes the night before to give 80-90% confluence for plasmid and 40-50% for miRNA at the day of transfection. The following day cells were transfected with miR-520c-3p mimics (50 nM), miR-520c-3p inhibitor (100 nM), miR-nc (50 nM), inhibitor-nc (100 nM), pcDNA3.1/HOXA-AS2 (4.0μg) or pcDNA3.1 (4.0 μg) respectively using Lipofectamine 2000 (invitrogen), according to the manufacturer's instructions. To perform effective lentivirus-mediated suppression of HOXA-AS2 in cells, the following HOXA-AS2 shRNA and scrambled control shRNA were inserted into the pLVX-tdTomato-Puro vector (Biowit, Shenzhen, China): HOXA-AS2 shRNA#1 forward, 5'-GAGUUCAGCUCAAGUUGAACAUACA-3' and reverse, 5'-UGUAUGUUCAACUUGAGCUGAACUC-3'; shRNA#2 forward, 5'-AAACCUUGUAGAUAGCUUGAGCUGG-3' and reverse, 5'-CCAGCUCAAGCUAUCUACAAGGUUU-3'; shRNA#3 forward, 5'-CAAGCUUGACAAGUUCAGCUCAA-3' and reverse, 5'-UUGAGCUGAACUCUUGUCAAGCUUG-3'; After transfection for 6 hours, the medium was replaced with normal culture medium. At 48 h post-transfection, cells were harvested for qRT-PCR analysis.
CCK-8 cell viability assay
After transfection, the cells mixed with 10 ml of CCK-8 solutions per well and incubated for further 1 h at 37 °C. The amount of formazan dye generated by cellular dehydrogenase activity was measured for absorbance at 450nm by a microplate reader (Molecular Devices, Sunnyvale, CA, USA). The optical density values of each well represented the survival/proliferation of cells.
Matrigel invasion assay
Cells were seeded (5 × 104 cells suspended in 0.5 ml of no FBS media) in duplicate into 12-well Corning BioCoat Matrigel Invasion Chambers with an 8 μm pore size polyethylene terephthalate membrane. As a chemotaxis factor, FBS (10%) was added to the lower compartment of the Matrigel Invasion Chambers. After 24 hours of incubation at 37°C in 5% CO2 cells that had migrated through the pores were stained by JorVet DipQuick Stain assay and counted under a microscope (six slides per well; each experiment was repeated six times).
Western blot analysis
For protein extracts, cells were collected, washed with 1× PBS, resuspended with 2× SDS loading buffer (125 mM Tris pH 6.8, 4% SDS, 20% glycerol, 200 mM dithiothreitol, 200 mM β-mercaptoethanol, 0.2% w/v bromophenol blue), and boiled for 10 minutes. Protein lysates were loaded onto 4-20% Criterion Tris-HCl precast gels (Bio-Rad), proteins were separated by electrophoresis (300V for 30 minutes), and subsequently transferred to 0.45 μm polyvinylidene fluoride membranes. Membranes were incubated in 5% milk solution of Tris-buffered saline buffer containing 0.1% Tween-20 (TBST) and incubated with primary antibodies diluted in 5% bovine serum albumin TBST solution containing 0.1% sodium azide overnight at 
Tumor formation assay
Female BALB/c nude mice were purchased at 5-6 weeks of age from Beijing Vital River Laboratory Animal Technology Co., Ltd. For xenograft models, 5 × 105 cells transfected with HOXA-AS2 shRNA as well as negative control (GenePharma) were subcutaneously injected in the bottom right back of BALB/c nude mice respectively. Tumor growth was examined every 3 days when the implantations were starting to grow bigger. After 4 weeks the mice were sacrificed, necropsies were performed and the tumor tissues were harvested. Tumor volumes were calculated as described previously.
RNA immunoprecipitation (RIP) assay
The RIP assay was performed to explore the interaction between HOXA-AS2 and miR-520c-3p by using EZ-Magna RIP RNA-binding protein immunoprecipitation kit (Millipore). Cells were lysed, and the cell lysis was then incubated with anti-human Ago2 antibodies (Millipore) coated on magnetic beads in RIP buffer. Input and normal IgG were used as controls. The precipitated RNAs were isolated and reverse transcribed in cDNA to analyze HOXA-AS2 and miR-520c-3p level using qRT-PCR.
Luciferase reporter assays
StarBase v2.0 (http://starbase.sysu.edu.cn/) was used to predict the binding sites between LncRNA-HOXA-AS2 and miR-520c-3p. The luciferase reporter assays were carried out with the help of the Dualluciferase Reporter Assay System (Promega, Madison, WI, USA). The wide-type HOXA-AS2 or mutant HOXA-AS2 that had the predicted miR-520c-3p binding site was established and integrated into a pmir-GLO Dual-luciferase vector to form the pmirGLO-HOXA-AS2-wild type (HOXA-AS2-wt) or pmirGLO-HOXA-AS2-mutant (HOXA-AS2-mut) reporter vector. Cotransfection of HOXA-AS2-wt or HOXA-AS2-mut was carried out with miR-520c-3p mimics or negative control into cells with the use of Lipofectamine 2000. Subsequent to transfection for a period of 48 hours, the luciferase activities were measured in accordance with the guidelines of the manufacturer. In the same manner, pmirGLO-S100A4-wild type (S100A4-wt) or pmirGLO-S100A4-mutant (S100A4-mut) were constructed, together with cotransfecting with miR-520c-3p mimics or negative control into HEK293T cells. 48 hours following the transfection, the relative luciferase activities were detected.
Immunohistochemistry
For each patient sample, three paraffin sections of 5 μm were prepared, one for hematoxylin and eosin (HE) staining and the other two for immunohistochemical staining. PBS instead of primary antibodies was used for negative control, and the breast cancer tissue was used for positive control. Sections were dewaxed using xylene, followed by hydration with ethanol solutions and addition of EDTA for antigen retrieval. Later, sections were blocked with normal goat serum for 30 min to eliminate non-specific binding. Sections were incubated with primary antibody against S100A4 (Abcam, Cambridge, UK). Sections were then incubated with biotin-labeled secondary antibodies for 30 min at room temperature, followed by staining with diaminobenzidine (DAB). Finally, the sections were counterstained with hematoxylin. The result of staining was determined by two doctors who did not know the clinical condition of patients. The proportions of positive cells of 0, 1-5, 6-25, 26-75, and 76-100 % were assigned with scores of 0, 1, 2, 3, and 4, respectively. Scores of 0-2 were considered as negative expression, and scores of 3-4 were considered as positive expression. 
Statistical analysis
The presentation of the data has been made as the mean ± SD from at least three sovereign experiments. Statistical analyses were carried out with the use of SPSS 18.0 software (SPSS, Chicago, IL, USA), together with generating the graphs using GraphPad Prism 6.0 (GraphPad Prism, San Diego, CA, USA). The relationship between HOXA-AS2 expression and clinical characteristics of patients was evaluated with the application of the chi-squared test. Analyses were carried out for the dissimilarities between groups through the application of Student's t test, one-way ANOVA analysis and Pearson's correlation analysis. P < 0.05 was considered statistically significant.
Results

LncRNA-HOXA-AS2 was up-regulated in human PTC tissues and cell lines
To determine the function of HOXA-AS2 during tumorigenesis of PTC, we first detected the expression of HOXA-AS2 in tumor tissues and adjacent normal tissues from 128 patients suffering from PTCs. Fig. 1A , qRT-PCR analysis displayed significantly higher levels of HOXA-AS2 in PTC tissues compared to normal tissues. We found that high expression of HOXA-AS2 was corrected with distant metastasis (*P < 0.05, Fig. 1B ). To investigate the roles of HOXA-AS2in PTC, we examined the correlation between clinical characteristics and HOXA-AS2 expression in 128 PTC patients. We used the mean expression level of HOXA-AS2 in cancerous tissues to dichotomise the PTC cases. Univariate analysis showed that high HOXA-AS2 expression group displayed a higher incidence of increased lymph node metastasis (P=0.001), multifocality (P=0.005) and advanced TNM stage (P=0.020). However, no significant differences were observed with regard to age, gender, or T stage (Table 1) .
Furthermore, to confirm the upregulation of HOXA-AS2 in PTC cell lines, we performed qRT-PCR analysis to detect the HOXA-AS2 expression in 4 PTC cell lines (BHP5-16, TPC, K1, BHP2-7) and a normal human thyroid cell line Nthy-ori 3-1. As illustrated in Fig. 1C , HOXA-AS2 mRNA expression level was significantly higher in four PTC cell lines as compared with Nthy-ori 3-1 (P < 0.01, respectively). BHP5-16 and K1 cells showed the higher expression of HOXA-AS2, in relation to TPC and BHP2-7 cells. To analyze the role of HOXA-AS2 in PTC, BHP5-16 and K1 cells were stably transfected with HOXA-AS2 shRNAs (respectively shHOXA-AS2 #1, shHOXA-AS2 #2, or shHOXA-AS2 #3) or empty vectors (sh-NC). To enhance HOXA-AS2 expression in PTC cells, a pcDNA3.1/HOXA-AS2 vector was constructed and transfected into TPC cells respectively. The cells transfected with pcDNA3.1 plasmid were acted as a control.
We detected HOXA-AS2 expression at 48h post-transfection by qRT-PCR analysis to analyze efficiency and revealed that HOXA-AS2 expression was significantly decreased in BHP5-16 and K1 cells, and HOXA-AS2 expression was significantly increased in TPC cells, as compared with control group respectively (Fig. 1D-E) . Moreover, shHOXA-AS2 #3 had higher efficiency of interference than shHOXA-AS2 #1 and #2 group (Fig. 1D) , so we chose shHOXA-AS2 #3 subsequently for the following experiments.
HOXA-AS2 regulates PTC progression in vitro and in vivo
To evaluate the biological effects of HOXA-AS2 in PTC cells, we compared the proliferation, migration and invasion ability of BHP5-16-shHOXA-AS2 #3 and K1-shHOXA-AS2 #3 cells with control cells. CCK-8 assays revealed that silencing of HOXA-AS2 expression significantly suppressed cell proliferation of BHP5-16 and K1 cells compared with the respective controls (P < 0.01, Fig. 1F and Fig. 2A ). Whereas, cell proliferation was significantly increased in TPC cells infected with pcDNA3.1/HOXA-AS2 vector compared with negative controls (P < 0.01, Fig. 2B) .
The above in vitro data showed that HOXA-AS2 functioned as a tumor oncogene in PTC cell lines. To further determine the effects of HOXA-AS2 on tumorigenesis in vivo, BHP5-16 cell lines transfected with either empty vector or shHOXA-AS2 #3 were subcutaneously implanted into nude mice. As expected, deregulation of HOXA-AS2 substantially attenuated the growth of tumors in nude mice as early as 4 weeks (P < 0.01, Fig. 2C-D) . Subsequently, The average expression level of HOXA-AS2 in sh-HOXA-AS2#3 group was lower than that in empty group (P < 0.01, Fig. 2F ).
HOXA-AS2 promotes PTC cell migration and invasion via regulating EMT
To further confirm the effect of HOXA-AS2 on PTC cell migration and invasion, we investigated cell migration and invasion by transwell assay. The results showed that the migratory and invasive capacities of BHP5-16 and K1 cells dramatically decreased after deregulation of HOXA-AS2 (P < 0.01, Fig. 3A-B) . Furthermore, the transwell 
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Cellular Physiology and Biochemistry assay showed that overexpression of HOXA-AS2 treatment significantly promoted the migration and invasive capacity of TPC cells compared to NC (P < 0.01, Fig. 3C ), suggesting that HOXA-AS2 could promote PTC cell migration and invasion. We next examined whether silencing HOXA-AS2 expression inhibited mesenchymal features. As expected, the mesenchymal marker Vimentin and N-cadherin were reduced in BHP5-16 and K1 cells after transfection of shHOXA-AS2 #3. The expression of E-cadherin increased in both cells (Fig. 3 C-D) . Overexpression of HOXA-AS2 treatment significantly decreased the expression of E-cadherin, and increased Vimentin and N-cadherin expression in TPC cells (Fig. 3 E) . In conclusion, our results suggest that inhibition of HOXA-AS2 decreased the ability of migration and invasion of PTC cells, and that this effect likely relies on reversing the EMT process.
The interaction between HOXA-AS2 and miR-520c-3p in PTC cells
To investigate the effect of HOXA-AS2 on the expression of miRNAs, BHP5-16 cells were transfected with either empty vector or shHOXA-AS2 #3 for 48 hrs. Hierarchical clustering of differentially expressed miRNAs is shown in Fig. 4A . Then, we applied the online software starBase v2.0. to predict the miRNAs that interacted with HOXA-AS2. The bioinformatics analysis revealed potential combination of HOXA-AS2 and miR-520c-3p, the putative binding sites as shown in Fig. 4B .
To verify whether HOXA-AS2 could directly interact with miR-520c-3p, we constructed luciferase vectors containing wild type or mutant binding sites of HOXA-AS2 in miR-520c-3p and performed luciferase reporter assay. As shown in Fig. 4C , miR-520c-3p overexpression significantly reduced the luciferase activity of pmirGLO-HOXA-AS2 reporter but had no obvious effect on their mutant reporters (pmirGLO-HOXA-AS2-mut). In a further RIP experiment, HOXA-AS2 and miR-520c-3p simultaneously existed in the production precipitated by anti-AGO2 (Fig. 4D) , suggesting that miR-520c-3p is HOXA-AS2-targeting miRNA. 
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Next, we measured the levels of miR-520c-3p expression in various PTC cell lines. As shown in Fig. 4E , the expression of miR-520c-3p was obviously decreased in BHP5-16 and K1 cells, indicating the opposite result to HOXA-AS2 expression. To explore the regulatory relationship between HOXA-AS2 and miR-520c-3p, BHP5-16 and K1 cells were transfected with either empty vector or shHOXA-AS2 #3, and qRT-PCR was used to detect the expression level of miR-520c-3p. The results showed that silencing of HOXA-AS2 increased the expression level of miR-520c-3p in BHP5-16 and K1 cells (P < 0.01, Fig. 4F ).
miR-520c-3p inhibits PTC progression by targeting S100A4
To investigate the role of miR-520c-3p on PTC carcinogenesis, miR-520c-3p mimics or inhibitor was transfected into PTC cell lines and the proliferation curves were performed using CCK8 assays. Our results showed that miR-520c-3p overexpression markedly inhibits the cell growth in both BHP5-16 and K1 cells when compared with cells transfected with Bioinformatics analysis revealed the predicted binding sites between S100A4 and miR-520c-3p; E: Luciferase reporter assay demonstrated miR-520c-3p mimics significantly decreased the luciferase activity of S100A4-wt in HEK293T cells; F: miR-520c-3p expression was significantly downregulated in PTC tissues compared with adjacent normal tissues by qRT-PCR analysis; G: S100A4 expression was significantly upregulated in PTC tissues compared with adjacent normal tissues by qRT-PCR analysis; H: IHC analysis were performed to examine the expression levels of S100A4 in PTC tissues and adjacent normal tissues; **P<0.01.
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HOXA-AS2 and Papillary Thyroid Cancer miR-nc, whereas the TPC cells transfected with miR-520c-3p inhibitor grew at a dramatically higher rate as compared with controls ( Fig. 5A-C) . Collectively, these data indicate that miR520c-3p can inhibit PTC cells proliferation, which inversely correlates with the effects of HOXA-AS2 in PTC cells.
To identify potential target genes of miR-520c-3p, we searched for candidate genes using TargetScan6.2 and miRBase miRNA databases. Bioinformatics analysis showed that miR-520c-3p directly targets S100A4 (Fig. 5D) . To confirm the predictions, a wild type or mutant S100A4 3′ UTR luciferase reporter vector was conducted. S100A4-wt or S100A4-mut was co-transfected with miR-520c-3p mimics or negative control into HEK293T cells. The relative luciferase activity was remarkably reduced in cells co-transfected with the S100A4-wt luciferase reporter and miR-520c-3p mimic than in the negative control cells. However, inhibitory effects were abolished when 3′-UTRs that contained both mutant-binding sites were co-transfected with miR-520c-3p, confirming that S100A4 is a target of miR-520c-3p (P<0.01; Fig. 5E) .
Furthermore, the qRT-PCR was performed to detect the expression of miR-520c-3p and S100A4 mRNA in tumor tissues and adjacent normal tissues from 128 patients suffering from PTCs. The miR-520c-3p was significantly lower in PTC tissues compared with adjacent normal tissues, and the S100A4 expression was significantly higher in PTC tissues (P<0.01; Fig. 5F -G). The immunohistochemistry results showed that S100A4 expression in PTC specimens was significantly upregulated compare with that in the adjacent normal tissues (93/128 VS. 25/128, P<0.01; Fig. 5H ). Thereafter, the Pearson's correlation analysis indicated that miR-520c-3p expression level had inverse correlation with the expression of S100A4 mRNA in PTC tissues. These evidences demonstrated that S100A4 was a direct target of miR-520c-3p in PTC.
Discussion
Although the majority of PTCs usually shows an excellent prognosis after treatment, there is approximately 30% cases with lymph node metastases which prognoses unfavorable outcomes [18] . The biological behavior of PTC varies widely. However, the ideal genetic marker for PTC prognosis has not yet been identified [19] . So it is quite critical to find new biomarkers for more accurate diagnosis and treatment for PTC.
LncRNAs (long noncoding RNAs) are broadly defined as noncoding RNA molecules longer than 200 nucleotides [20, 21] . They are key elements in cell differentiation and ontogenetic process through interactions with DNA, chromatin, regulatory proteins and a variety of cellular RNA species. More and more evidence has demonstrated that lncRNA have close relationship with the occurrence and development of a variety of cancers, including PTC. For example, it has been reported that lncRNA NEAT1_2 expression is up-regulated in PTC and it promotes cancer cell proliferation and tumorgenesis by functioning as a ceRNA to regulate ATAD2 expression by sponging miR-106b-5 [22] . Li et al. found that lncRNA HIT000218960 could promotes the malignant development of PTC by upregulating the expression of HMGA2 [23] . LncRNA Gas5 also has been shown to play a tumor suppressive role in PTC cells by acting as a sink for miR-222-3p, modulating the expression of PTEN [13] . HOXA-AS2, a 1048-bp lncRNA that serves as an apoptosis repressor in all-trans retinoic acid-treated NB4 promyelocytic leukemia cells, has been reported to be overexpressed in various types of malignant tumours, and promoted tumorigenesis and development [11, 24] . However, the expression of lncRNA HOXA-AS2 in PTC patients and its precise molecular mechanisms have not been completely elucidated.
In our study, we reported that HOXA-AS2 expression in PTC samples and cell lines was upregulated compared to that in surrounding non-tumor tissues as well as Nthy-ori 3-1 normal human thyroid epithelium cells. Furthermore, we found that the mechanism by which HOXA-AS2 promotes tumor progression of PTC in vitro and in vivo is mediated by inhibiting miR-520c-3p expression, thus, influenced downstream genes S100A4 expression. All these results supported the conclusion that HOXA-AS2 served as an oncogene in PTC to promote PTC cell proliferation. Several studies are in agreement with our results, indicating that HOXA-AS2 affects the motility of cancer cells, which were key molecules in tumor metastasis. In this study, HOXA-AS2 knockdown inhibits the migratory and invasive ability of PTC cells, indicating that high expression of HOXA-AS2 could promote PTC cell migration and invasiveness ability. HOXA-AS2 might also play an important role in the regulation of EMT. HOXA-AS2 certainly increased the expression level of vimentin and N-cadherin, and inhibit E-Cadherin expression.
The ceRNA hypothesis proposed by Pandolfi et al. suggests that endogenous RNA molecules have miRNA binding sites, which could be competitive with miRNAs, thus indirectly regulating the target gene expression of miRNAs [12] . The ceRNA hypothesis confers new and more extensive biological functions of mRNAs and non-coding RNAs. We performed a microarray to screen the HOXA-AS2-regulated miRNAs in PTC. Bioinformatics analysis (Starbase 2.0, RNA22) of miRNA recognition sequences on HOXA-AS2 revealed the presence of more than 30 miRNAs binding sites. Among them, miR-520c-3p stood out through detailed survey, which was considered to facilitate tumor accelleration effect in PTC. Luciferase assays were also used to validate the direct binding ability of the miR-520c-3p response elements on the full-length HOXA-AS2 transcript. We also confirmed that miR-520c-3p was significantly downregulated in the PTC tissues compared with the normal tissues, and miR520c-3p was a tumor suppressor gene in PTC by suppressing cell proliferation, which was consistent with results of knockdown of HOXA-AS2 expression in PTC cells.
It was well established that miRNAs function in post-transcriptional regulation mainly via directly binding to the 3'-UTR of target mRNAs, resulting in mRNA degradation or translational inhibition. To explore the potential target genes of miR-520c-3p, we used several different miRNAs target predicting software and selected out S100A4 as a downstream target of miR-520c-3p. Moreover, we further used luciferase reporting assay to illustrate S100A4 as a potential target gene of miR-520c-3p. S100A4 was previously reported to be an important protein with the capacity to promote invasion and metastasis of many human neoplasms, including PTC. In our study, the immunohistochemistry results showed that S100A4 expression in PTC specimens was significantly upregulated compare with that in the adjacent normal tissues.
Conclusion
In conclusion, this study highlights a pivotal role of HOXA-AS2 in various aspects of tumorigenesis such as proliferation, migration, invasion, and in vivo tumor growth in PTC through the post-transcriptional regulation of miR-520c-3p/S100A4 axis. Additionally, we demonstrated that silencing of HOXA-AS2 as possible mechanism during carcinogenesis, by functioning as a ceRNA to regulate ATAD2 expression by sponging miR-106b-5p. Targeting NEAT1_2 could be a promising therapeutic strategy to treat PTC.
